A Phase II International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

Share
Print

Full Title

LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

Purpose

Histiocytosis is a general name for a group of diseases that involve an abnormal increase in the number of immune cells called histiocytes. Langerhans cell histiocytosis (LCH) is a rare blood cancer that forms when a type of white blood cell called Langerhans cells becomes abnormal and grows in different parts of the body. LCH is most common in young children, but can occur at any age.

The purpose of this study is to evaluate the effectiveness of various combination treatments for children and adolescents with LCH. Examples of some of the medications to be assessed include vinblastine, prednisone, 6-mercaptopurine, vincristine, cladribine, and cytarabine.

Each patient’s treatment will be based on the stage of the disease and how much it affects multiple organ systems. In some parts of the study, patients are randomly assigned to one treatment group versus another. Some of the medications in this study are given intravenously (by vein) and others are taken orally (by mouth). The goal of the study is to see how well these new treatment combinations reduce the risk of LCH recurrence and long-term disease-related problems.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have LCH that was diagnosed before age 18.

For more information about this study and to inquire about eligibility, please contact Dr. Christopher Forlenza at 212-639-5226.

Protocol

18-354

Phase

II

Co-Investigators